 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Gilead Sciences Inc. (GILD) is a biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. 
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
On October 27th, GILD reported 3rd Quarter September 2022 earnings of $1.90 per share on revenue of $7.0 billion. The consensus earnings estimate was $1.44 per share on revenue of $6.1 billion.
It guided higher. The company said it expects 2022 earnings of $6.95 to $7.15 per share on revenue of $25.90 billion to $26.20 billion. The company's previous guidance was earnings of $6.35 to $6.75 per share on revenue of $24.50 billion to $25.00 billion.
On November 2nd, FDA approved the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease.
The above mentioned positive events have sent shares into a bullish "flag" and higher share prices are expected.
Entry Point: $80.00
Stop Loss: $76.00
Trading Range: $57.165 to $81.32
Target Price: $88.00
